Avid Bioservices, INC

Avid Bioservices has been acquired by funds managed by GHO Capital and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion, leading to its delisting from Nasdaq.

Avid Bioservices has been acquired by funds managed by GHO Capital and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion, leading to its delisting from NASDAQ.

Avid Bioservices stockholders approved the merger agreement with GHO Capital Partners and Ampersand Capital Partners, paving the way for the company to become a wholly-owned subsidiary.

Avid Bioservices announced a 32% increase in second-quarter revenue and a definitive agreement to be acquired by GHO Capital Partners and Ampersand Capital Partners for approximately $1.1 billion.

Avid Bioservices has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion.

Avid Bioservices' stockholders approved amendments to the 2018 Omnibus Incentive Plan and the 2010 Employee Stock Purchase Plan, and elected directors at the 2024 Annual Meeting.

Avid Bioservices saw a 32% increase in revenue for the second fiscal quarter, reaching $33.5 million, while also announcing a pending merger agreement.

Avid Bioservices saw a 6% increase in revenue to $40.2 million in the first fiscal quarter, driven by growth in process development, and ended the quarter with a backlog of $219 million.

Avid Bioservices reported a net loss for the third quarter of fiscal year 2024, driven by decreased revenue and increased costs, while also addressing a debt default through a new convertible note offering.

Avid Bioservices has amended its Q2 financials to correct the classification of its 2026 convertible notes as a current liability and to adjust for understated interest expenses.

Avid Bioservices has restated its first quarter 2024 financials due to an error in classifying its 2026 convertible notes as long-term debt instead of a current liability.

Avid Bioservices' fiscal year 2024 saw a decrease in revenue and a net loss, impacted by fewer manufacturing runs and increased costs, despite completing a major facility expansion.

Avid Bioservices has amended its 2023 annual report to restate its financials due to a misclassification of debt and understated interest expense.

Mark Ziebell, VP and General Counsel of Avid Bioservices, reports the disposal of common stock, stock options, restricted stock units, and performance stock units due to the merger with Space Mergerco, Inc.

Director Jeanne Thoma reports the disposal of Avid Bioservices shares, stock options, and restricted stock units due to the merger with Space Mergerco, Inc.

Director Gregory Sargen reports the disposal of common stock, stock options, and restricted stock units due to the merger of Avid Bioservices, Inc. with Space Mergerco, Inc.

Richard A. Richieri, Chief Operations Officer of Avid Bioservices, Inc., reports the disposal of common stock, stock options, restricted stock units, and performance stock units due to the merger with Space Mergerco, Inc.

Director Catherine Mackey reports the disposal of Avid Bioservices shares, stock options, and restricted stock units due to the merger with Space Mergerco, Inc.

Matthew Kwietniak, Chief Commercial Officer of Avid Bioservices, reports the disposal of common stock, restricted stock units (RSUs), and performance stock units (PSUs) due to the merger with Space Mergerco, Inc., resulting in a cash payment of $12.50 per share.

Avid Bioservices supplements its proxy statement to address stockholder demands and lawsuits challenging the proposed merger with Space Finco, Inc., a subsidiary formed by affiliates of GHO Capital Partners LLP and Ampersand Management LLC.

Avid Bioservices reminds stockholders to vote in favor of the proposed acquisition by GHO Capital Partners LLP and Ampersand Capital Partners at the special meeting scheduled for January 30, 2025.

Avid Bioservices encourages stockholders to vote in favor of the proposed acquisition by GHO Capital Partners and Ampersand Capital Partners, supported by recommendations from ISS and Glass Lewis.

Avid Bioservices files an investor presentation highlighting the benefits of its proposed acquisition by GHO Capital Partners and Ampersand Capital Partners, urging stockholders to vote in favor of the transaction.

Avid Bioservices is set to be acquired by Space Finco, Inc., backed by GHO and Ampersand, for $12.50 per share in cash, representing a significant premium to its recent trading price.

Avid Bioservices announces the expiration of the Hart-Scott-Rodino waiting period, bringing its acquisition by GHO Capital Partners and Ampersand Capital Partners closer to completion.